Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The disclosure states that Panmure Gordon (UK) Limited, as an exempt principal trader, has made purchases and sales of Allergy Therapeutics plc's 0.1p ordinary shares. The disclosure indicates that Panmure Gordon (UK) Limited made purchases of 0 securities and sales of 171,541 securities at a highest price per unit of 0.0283 and a lowest price per unit of 0.0283 on September 8, 2023.

The disclosure does not mention any cash-settled derivative transactions or stock-settled derivative transactions (including options) related to Allergy Therapeutics plc's securities. It also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities between Panmure Gordon (UK) Limited and any party to the offer or any person acting in concert with a party to the offer.

The disclosure was made on September 11, 2023, and the contact person for further information is Lauren Riley, with a telephone number of 020 7886 2963. The disclosure also mentions that public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service, and the Panel's Market Surveillance Unit is available for consultation regarding the Code's dealing disclosure requirements.